Supplementary Figure 6: Tolerability assessment in animals treated with the SHP2 inhibitor. | Nature Cell Biology

Supplementary Figure 6: Tolerability assessment in animals treated with the SHP2 inhibitor.

From: RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers

Supplementary Figure 6

Repeated daily oral administration of RMC-4550 of all dose groups in the MeWo (a), NCI-H1838 (b), NCI-H358 (c), and MIA PaCa-2 (d), xenograft models and LUN023 (e), LUN037 (f), TH77 (g), LUN092 (h), and LUN156 (i) PDX models was well tolerated as assessed by body weight. Source data is provided in Supplementary Table 9.

Back to article page